News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Biotechnology company, Capricor Therapeutics Inc. (CAPR), Tuesday announced that it had been granted an in-person Type-B meeting with the U.S. Food and Drug Administration regarding the commercial launch of CAP-1002.
The company stated that it plans to accelerate the process of Biologics License Application or BLA submission with this meeting.
Earlier, CAP-1002 drug had received Regenerative Medicine Advanced Therapy or RMAT, and orphan drug designations for the treatment of patients with Duchenne muscular dystrophy or DMD, which is a genetic disorder involving muscle weakness and degeneration.
Currently, Capricor's stock is trading at $4.3877, up 10.80 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
